
Pharmaceutical companies say AI has cut early drug-discovery timelines, with some reporting development work taking half as long. Novo Nordisk said it reduced molecule-design cycles from around eight to three and shortened each cycle from eight weeks to four.
Scientists at large pharmaceutical companies say AI is being used to design and prioritize molecules and identify safety risks, beyond administrative tasks. Novartis said the average time from starting a project to producing a drug candidate has fallen from three years to about 18 months to two years.
Sanofi said an AI-enabled approach saved at least a year in developing asthma treatment lunsekimig by allowing it to skip a dose-selection study. Novartis said AI helped identify five kidney-disease targets it prioritized, while Bristol Myers Squibb said one of its sickle cell anemia candidates would not have been developed without its AI systems. Researchers identified 129 AI drug candidates across 69 companies in March, up from around 117 eight months earlier; most remain in early development.
Anthropic is working on drug development independently and with partners including Bristol Myers Squibb, and its models are also used by companies including Novo Nordisk. Pharmaceutical executives described AI companies as potential collaborators and competitors. Sanofi's Matt Truppo expects AI to cut early-discovery timelines by 20% to 25% within two years and perhaps by half within five years across more than 100 programs.